---
title: "EXCLUSIVE-'No discussions' over AstraZeneca-Bristol Myers deal, senior source says"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294963289.md"
datetime: "2026-08-05T12:03:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294963289.md)
  - [en](https://longbridge.com/en/news/294963289.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294963289.md)
---

# EXCLUSIVE-'No discussions' over AstraZeneca-Bristol Myers deal, senior source says

By Maggie Fick and Sabrina Valle

Aug 5 (Reuters) - There are “no discussions” ongoing between AstraZeneca (AZN.L) and Bristol Myers Squibb (BMY.N) over a potential deal, a senior source close to the matter told Reuters on Wednesday, quashing the prospect of a mooted mega merger between the drugmakers.

“There is no deal between AstraZeneca and BMS. There never was a deal to be done, and there are no discussions between the companies,” said the source, speaking on condition of anonymity.

On Sunday Reuters reported, citing a person familiar with the situation, that the two drugmakers had held preliminary talks about a possible deal that would create a pharmaceutical behemoth with a combined value of nearly $400 billion.

Reuters was unable to ascertain at that time if the discussions remained ongoing.

The Financial Times first reported news of the talks.

AstraZeneca shares slid around 9% after the reports of the deal talks, while Bristol Myers shares had held more steady.

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [AZNH.US](https://longbridge.com/en/quote/AZNH.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [Ascent Group LLC Has $3.21 Million Stake in Bristol Myers Squibb Company $BMY](https://longbridge.com/en/news/295994083.md)
- [AstraZeneca held talks with Bristol-Myers through spring, summer - FT](https://longbridge.com/en/news/295571239.md)
- [AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies](https://longbridge.com/en/news/296114723.md)
- [FDA grants accelerated approval to Bristol Myers Squibb’s ZENBEXUS for relapsed multiple myeloma combo use](https://longbridge.com/en/news/295848217.md)
- [North Dakota State Investment Board Boosts Holdings in Bristol Myers Squibb Company $BMY](https://longbridge.com/en/news/296020226.md)